Evaxion significantly expands vaccine development collaboration with MSD
26. September 2024 07:30 ET
|
Evaxion Biotech
Agreement provides MSD with options to license Evaxion’s preclinical, AI-designed vaccine candidates EVX-B2 and EVX-B3Evaxion will host a conference call and webcast to discuss the agreement on...
Automatic Immunoassay Analyzer Market to Reach $51.4 Billion, Globally, by 2033 at 15.3% CAGR: Allied Market Research
19. September 2024 06:41 ET
|
Allied Analytics LLP
Wilmington, Delaware, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Allied Market Research published a report, titled, "Automatic Immunoassay Analyzer Market by Product (Immunofluorescence, Chemiluminescence,...
60 Degrees Pharmaceuticals, Inc. Announces $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules
04. September 2024 08:00 ET
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharmaceuticals raises $4M through private placement for working capital, commercialization, and R&D, with H.C. Wainwright as placement agent.
Avance Clinical Announces Senior Appointment to North American Operations
31. Juli 2024 02:45 ET
|
Avance Clinical
ADELAIDE, Australia and WAKE FOREST, N.C., July 31, 2024 (GLOBE NEWSWIRE) -- Avance Clinical, an award-winning, mid-sized full-service global Contract Research Organization (CRO) for biotech...
Pneumagen Highlights Broad-Spectrum Antiviral Activity of First-in-Class Intranasal Drug Neumifil in New Publication
03. Juli 2024 04:00 ET
|
Pneumagen Ltd
Pneumagen has previously reported positive results from both Phase 1 and a clinical proof of concept Phase 2 Human Influenza Challenge study demonstrating the potential of NeumifilNew preclinical...
Pneumagen Presents Positive Phase 2 Influenza Human Challenge Study data on Neumifil, its Broad-Spectrum Antiviral Drug, at the American Thoracic Society (ATS) 2024 Conference
23. Mai 2024 07:00 ET
|
Pneumagen Ltd
Neumifil delivers statistically significant reductions in influenza symptomatic infection rate, symptom severity and viral loadStrategy to advance clinical development of Neumifil to be based on...
Pneumagen to Present Phase 2 Clinical Data on Neumifil, its Broad-Spectrum Antiviral, Intranasal Drug for Viral Respiratory Tract Infections, at ATS 2024
02. Mai 2024 07:00 ET
|
Pneumagen Ltd
Data to be presented in oral and ePoster presentations St Andrews, UK – 2 May 2024 - Pneumagen, a clinical stage biotech company developing Neumifil, a broad-spectrum antiviral, intranasal drug for...
PharmaTher’s Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine
01. Mai 2024 08:00 ET
|
PharmaTher Holdings Ltd.
TORONTO, May 01, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, announced today Sairiyo...
Infectious Disease Connect Expands Telemedicine Services
16. April 2024 09:15 ET
|
Infectious Disease Connect
PITTSBURGH, April 16, 2024 (GLOBE NEWSWIRE) -- Infectious Disease Connect (ID Connect), a leading infectious diseases telemedicine and software solutions company, has expanded its services to meet...
Exosomes Market revenue to hit USD 5.3 Billion by 2036, says Research Nester
08. Januar 2024 05:30 ET
|
Research Nester
New York, Jan. 08, 2024 (GLOBE NEWSWIRE) -- The global exosomes market size is slated to expand at ~16% CAGR between 2024 and 2036. The market is poised to garner a revenue of USD 5.3 billion by the...